Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 683 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Crohn´s Disease Clear all
Completed No phase listed Observational Results available

Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

NCT03801928
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Inflectra
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
San Diego, California • Hamden, Connecticut • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

NCT01369355
View directory record Official record
Conditions
Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
Interventions
Placebo SC, Placebo IV, Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
77
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 2, 2026, 2:43 PM EDT
Terminated Phase 3 Interventional

Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim

NCT00206713
View directory record Official record
Conditions
Crohn Disease
Interventions
Sargramostim (Leukine), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 2, 2026, 2:43 PM EDT
Completed No phase listed Observational

A Long-term Safety Study of Infliximab (Remicade)

NCT00261976
View directory record Official record
Conditions
Arthritis, Rheumatoid, Crohn Disease, Psoriasis
Interventions
Infliximab (Remicade)
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
Not listed
Enrollment
2,971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Not applicable Interventional Results available

Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children

NCT02182947
View directory record Official record
Conditions
IBD
Interventions
Capsule endoscopy
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
4 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

NCT00587041
View directory record Official record
Conditions
Nephrolithiasis, Hyperoxaluria, Crohn's Disease
Interventions
Oxadrop, Agri-King Synbiotic (AKSB), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)

NCT00950105
View directory record Official record
Conditions
Crohn's Disease
Interventions
CPSI-2364 or placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 2, 2026, 2:43 PM EDT
Active, not recruiting Phase 3 Interventional

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
123
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 1Phase 2 Interventional

STA-5326 in Crohn's Disease Patients

NCT00088062
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Tucson, Arizona • Anaheim, California • North Miami Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 2:43 PM EDT
Terminated No phase listed Observational

PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease

NCT01759017
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease

NCT00074542
View directory record Official record
Conditions
Crohn's Disease
Interventions
Epanova™ (Omega-3 Free Fatty Acids)
Drug
Lead sponsor
Tillotts Pharma AG
Industry
Eligibility
16 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • Urbana, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2007 · Synced Oct 2, 2026, 2:43 PM EDT
Active, not recruiting Phase 3 Interventional

A Long-term Extension Study of Ustekinumab in Pediatric Participants

NCT05092269
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease

NCT00543374
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, PROCHYMAL adult human mesenchymal stem cells
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
53
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System

NCT04573959
View directory record Official record
Conditions
Intestinal Disease, Inflammatory Bowel Diseases, Crohn Disease, Ulcer, Celiac Disease
Interventions
SV-3 Capsule Endoscopy
Device
Lead sponsor
Capso Vision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Saratoga, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Not applicable Interventional Results available

A Trial of Yoga in Pediatric Inflammatory Bowel Disease

NCT03338894
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Yoga
Behavioral
Lead sponsor
Atlantic Health System
Other
Eligibility
10 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Morristown, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 2, 2026, 2:43 PM EDT
Terminated Not applicable Interventional

Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients

NCT03566407
View directory record Official record
Conditions
Crohn's Disease
Interventions
Colonoscopy
Procedure
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Ventura, California • Hamden, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease

NCT00072839
View directory record Official record
Conditions
Crohn's Disease
Interventions
ALX-0600, placebo, teduglutide 0.05, teduglutide 0.2 mg, Teduglutide 0.05 dose, teduglutide 0.1 mg dose
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
21
States / cities
Tucson, Arizona • Lakewood, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 2, 2026, 2:43 PM EDT
Enrolling by invitation Phase 4 Interventional

INSIGHT-IBD Pragmatic Study

NCT07686757
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions
Mirikizumab, Anti-TNF agents, anti-integrin antibodies, IL-12, IL-23
Drug
Lead sponsor
Specialty Networks Research.
Network
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Sun City, Arizona • Glenview, Illinois • Gurnee, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891
View directory record Official record
Conditions
Moderately to Severely Active Crohns Disease
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
61
States / cities
Dothan, Alabama • Glendale, Arizona • Lancaster, California + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Recruiting Phase 2 Interventional

Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease

NCT07556718
View directory record Official record
Conditions
Quiescent Crohn's Disease (CD)
Interventions
Amitriptyline, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Completed No phase listed Observational

A Study of Ustekinumab Treatment in Children With Crohn's Disease

NCT05242458
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 25 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 2, 2026, 2:43 PM EDT
Recruiting No phase listed Observational

Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

NCT07619547
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Enrolling by invitation Not applicable Interventional

Utility of Random Biopsies in Patients With Inflammatory Bowel Disease

NCT06560021
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Biopsy strategy
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
1,642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Terminated Early Phase 1 Interventional

Maintenance Dosing of Vitamin D in Crohn's Disease

NCT03615378
View directory record Official record
Conditions
Crohns Disease, Vitamin D Deficiency
Interventions
5000 IU D3, 1000 IU D3, Placebo
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 2, 2026, 2:43 PM EDT